Are we undermining the value of palliative care through advanced cancer clinical trial consent language?

Puja J Umaretiya; Jennifer P Rubin; Jennifer M Snaman; Christina Ullrich; Angela M Feraco; Veronica Dussel; Joanne Wolfe; Elisha Waldman

doi:10.1002/cncr.33482

Are we undermining the value of palliative care through advanced cancer clinical trial consent language?

Cancer. 2021 Jun 15;127(12):1954-1956. doi: 10.1002/cncr.33482. Epub 2021 Mar 10.

Authors

Puja J Umaretiya^{1

2

3}, Jennifer P Rubin⁴, Jennifer M Snaman^{1

2

3}, Christina Ullrich^{1

2

3}, Angela M Feraco^{1

2}, Veronica Dussel^{2

5}, Joanne Wolfe^{2

3}, Elisha Waldman⁶

Affiliations

¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
² Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
³ Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁴ Department of Pediatric Neurology, Northwestern Feinberg School of Medicine, Chicago, Illinois.
⁵ Centro de Investigación e Implementación en Cuidados Paliativos, Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina.
⁶ Division of Palliative Care, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.

PMID: 33689176
DOI: 10.1002/cncr.33482

No abstract available

Keywords: advanced cancer; clinical trials; informed consent; palliative care; symptom management.

MeSH terms

Humans
Informed Consent
Language
Neoplasms* / therapy
Palliative Care*